# Journey Medical Corp (DERM)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/journey-medical-corp/ JSON: https://steadybase.io/company/journey-medical-corp.json Checked Nov 10, 2026. Latest filing read: Aug 12, 2026.

## Company

- Legal name: Journey Medical Corp
- Ticker: DERM (Nasdaq)
- SEC CIK: 0001867066
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Scottsdale, AZ
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Website: journeymedicalcorp.com
- LinkedIn: https://www.linkedin.com/company/journey-medical-corporation
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $61.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.html
- Operating income: -$8.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.html
- Net income: -$11.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.html
- SG&A: $44.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.html
- Employees: 58 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- Auditor: Kpmg LLP, Short Hills, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm

## Business

S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $61.9M | -$8.2M | -$11.4M | $44.4M |
| Dec 31, 2024 | $56.1M | -$13.7M | -$14.7M | $40.2M |
| Dec 31, 2023 | $79.2M | -$2.1M | -$3.9M | $43.9M |
| Dec 31, 2022 | $73.7M | -$27.5M | -$29.6M | $59.5M |
| Dec 31, 2021 | $63.1M | -$34.9M | -$44.0M | $39.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/journey-medical-corp.json

## Officers and directors

- Claude Maraoui, President & CEO. LinkedIn: https://www.linkedin.com/in/claudemaraoui. Source: Form 4 filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926048731/0001104659-26-048731-index.htm
- Joseph Benesch, CFO. Source: Form 4 filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926048733/0001104659-26-048733-index.htm
- Ramsey Alloush, Chief Operating Officer. LinkedIn: https://linkedin.com/in/ramsey-alloush-8065256. Source: Form 4 filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926048736/0001104659-26-048736-index.htm
- Lindsay A. Rosenwald, M.D., Executive Chairman. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- Justin Smith, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- Michael Pearce, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- Miranda Toledano, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- Neil Herskowitz, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm

## Recent 8-K events

- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm
- Jun 26, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926077888/tm2619038d1_8k.htm
- May 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_8k.htm
- Apr 21, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926046158/tm2612310d1_8k.htm
- Mar 25, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_8k.htm
- Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/tm2530914d1_8k.htm
- Sep 26, 2025: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465925093891/tm2527082d1_8k.htm
- Aug 28, 2025: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465925084879/tm2524202d2_8kseq1.htm
- Aug 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_8k.htm
- Jul 14, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1867066/000110465925067767/tm2520913d1_8k.htm

## Latest filings

- 8-K filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm
- 10-K filed Mar 26, 2026: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm
- 10-Q filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/1867066/000110465926094948/derm-20260630x10q.htm
- DEF 14A filed Apr 30, 2026: https://www.sec.gov/Archives/edgar/data/1867066/000110465926052883/tm261508-3_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/